Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program

Strategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing new treatment options to patients

Five Prime to receive up to $1.74 billion for FPA008, inclusive of $350 million upfront and potential development and regulatory milestone payments; additional double-digit royalties on future sales and option to co-promote in the U.S.

Five Prime to continue development of FPA008 in pigmented villonodular synovitis (PVNS) and in potential combinations with its own immuno-oncology candidates

Published: 15 October 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Five Prime Therapeutics Inc ( FPRX )

European Medicines Agency Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

10-year market exclusivity in Europe following marketing authorization in 31 European Economic Area (EEA) countries

PETACH TIKVA, Israel, Oct. 12, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.  

CF102 will benefit from protocol assistance and a 10-year market exclusivity following market authorization in the 28 European Union (EU) Member states, as well as 3 additional European Economic Area (EEA) countries.

Published: 12 October 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Can-Fite BioPharma Ltd ( CANF )

Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia

Study Meets Primary Endpoint, Submission of New Drug Application Planned for 2016
Company to Host Conference Call and Webcast Thursday, October 8th at 8:00 AM EDT/ 5:00 AM PDT

SAN DIEGO, Oct. 8, 2015 -- Neurocrine Biosciences, Inc. (NBIX) announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

Published: 08 October 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Neurocrine Biosciences Inc ( NBIX )

Can-Fite to Deliver 2 Presentations on its Cancer Drug CF102 at the 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine on October 8-10, 2015 in Athens

PETACH TIKVA, Israel, Oct. 7, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the Company's Director of Molecular Biology Labs, Shira Cohen, will deliver the following two scientific presentations at the 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine on October 8-10, 2015 in Athens, Greece:

Evoke Pharma Strengthens Financial Position

Provides Additional Support for Completion of Phase 3 Trial and Submission of New Drug Application (NDA)

SOLANA BEACH, Calif., Oct. 7, 2015 -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the amendment of its loan and security agreement with Square 1 Bank (the "credit facility") to extend the interest-only payment term for an additional 12 months. Furthermore, through cash management and At-The-Market equity placements under its agreement with MLV & Co. LLC, Evoke had an estimated $10.7 million in cash as of September 30, 2015, an increase of $0.8 million from June 30, 2015. The Company now projects that its current cash resources should be sufficient to fund operations through October 2016.

Published: 07 October 2015
Written by Editor
Nasdaq   Up on News   Financial  
Read more: Evoke Pharma Inc ( EVOK )
  1. Spark Therapeutics ( ONCE )
  2. ContraVir Pharmaceuticals Inc ( CTRV )
  3. BioAmber Inc ( BIOA )
  4. Incyte Corporation ( INCY )
  5. XenoPort Inc ( XNPT )